Transaction value for physician samples governs excise valuation where manufacturers sell to distributors for consideration.

Physician sample packs sold by a manufacturer to distributors were assessable on the transaction value charged to those distributors under Section 4(1)(a) of the Central Excise Act, 1944. The later free distribution of samples by the distributors to doctors was extraneous to valuation and did not justify shifting the assessment to Section 4(1)(b) or applying a pro rata trade-pack value. The reasoning followed the Supreme Court's view on the same factual pattern: once consideration is charged by the assessee from the distributors, valuation remains under Section 4(1)(a) and not the residual valuation mechanism.

---

---

Issues: Whether physician sample packs sold by the manufacturer to distributors were assessable under Section 4(1)(a) of the Central Excise Act, 1944 on the transaction value charged to the distributors, or under Section 4(1)(b) of the Central Excise Act, 1944 by adopting a pro rata value of trade packs.

Analysis: The dispute turned on the nature of the sale between the manufacturer and its distributors. The goods were admittedly sold for a price to the distributors, and the subsequent free distribution of physician samples by the distributors to doctors was held to be extraneous to valuation. On the same factual pattern, the Supreme Court had already held that where consideration is charged by the assessee from the distributors, the case falls within Section 4(1)(a) of the Central Excise Act, 1944 and does not go to Section 4(1)(b) or the valuation rules.

Conclusion: The physician sample packs were correctly assessable under Section 4(1)(a) of the Central Excise Act, 1944 on transaction value, and the Revenue's contrary valuation under Section 4(1)(b) was unsustainable.

---